<i>Weizmannia coagulans</i> BC99 regulates oxidative stress and serum metabolic pathways to improve allergic rhinitis: a randomized, double-blind, placebo-controlled trial.

ABSTRACT:

Background

Probiotics have demonstrated potential application value in alleviating allergic diseases, but their mechanisms of action remain to be explored. This study aimed to investigate the clinical efficacy of probiotics in patients with allergic rhinitis (AR) and explore the underlying mechanisms.

Methods

We evaluated the clinical intervention efficacy of Weizmannia coagulans BC99 (BC99) in adults with AR through a randomized, double-blind, placebo-controlled trial. Seventy-eight AR patients were randomly assigned to either the BC99 gummies group (n = 40) or the placebo group (n = 38) for an 8-week intervention. Rhinitis symptom survey questionnaires, including the Total Nasal Symptom Score (TNSS), the Rhinitis Quality of Life Questionnaire (RQLQ), and the Rhiniti

SUBMITTER: Li X 

PROVIDER: S-EPMC12592054 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature